EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Life Sciences - Clinical, TNT Asia
Director
Clinical trials have very detailed and precise processes and the logistical elements of these processes are critical Recent revisions to the pharmaceutical industrys regulatory laws as well as improved patent laws in countries such as Japan China and India have led to the burgeoning clinical trials market in Asia
Articles
Multi-Target Directed Ligands and Lipidomics Approach for Glioblastoma Drug Discovery
The traditional pharmaceutical approach of designing a diseasesymptomspecific drug has historically proven effective However this methodology often falls short due to the complex and often multifactorial etiology of diseases
Research Insights
Partitioning stable and unstable expression level variation in cell populations: A theoretical framework and its application to the T cell receptor
Phenotypic variation in the copy number of gene products expressed by cells or tissues has been the focus of intense investigation To what extent the observed differences in cellular expression levels are persistent or transient is an intriguing question
Case Studies
Rapid, Comprehensive, And Aff Ordable Mycobacterial Diagnosis With Whole-genome Sequencing: A Prospective Case Study
Abstract Background Slow and cumbersome laboratory diagnostics for Mycobacterium tuberculosis complex MTBC risk delayed treatment and poor patient outcomes Wholegenome sequencing WGS could potentially provide a rapid and comprehensive diagnostic solution In this prospective study we compare realtime
Techno Trends
Bayer Introduces Breakthrough Therapy BAY 2927088 for Non-Small Cell Lung Cancer
Bayer has introduced a groundbreaking therapy named BAY for addressing adult patients afflicted with unresectable or metastatic nonsmall cell lung cancer
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Nanotechnology based Drug Delivery for Infectious Diseases
Dr. Vinod Kumar Rajana, Assistant Professor of Pharmaceutics, specializes in nanotechnology, bioassays, and infectious disease research. With expertise in nanoparticle synthesis, biotechnology, and drug delivery, his work integrates green chemistry with pharmaceutical innovation to develop sustainable, low-cost nanomaterials for topical antifungal and anticancer therapies, water purification, and biomedical applications.
Smart Polymeric Nanocomposites for Cancer Therapeutics
Saurabh Shivalkar is a research fellow at Department of Applied Sciences, IIIT Allahabad, India. He did his M. Tech (Biomedical Engineering) from IIIT Allahabad. He has recently filed patent and published multiple papers in the allied areas of biomedical engineering and nanobiotechnology.
Sneha Ranjan is currently pursuing M.Sc. (Biotechnology) at Department of Biotechnology of Babasaheb Bhimrao Ambedkar University, Lucknow. She has worked on projects such as purification and characterisation of enzyme, production of recombinant proteins for diagnostics and therapeutics. She is currently working on polymeric nanocomposites for cancer therapeutics.
Current Research on Plant miRNA and Its Application in Disease Prevention
Atiya Saiyed is a Ph D student at Iladevi Cataract and IOL Research Centre and registered at Manipal Academy of Higher Education, Manipal. She is Senior Research Fellow from Indian Council of Medical Research, New Delhi. Atiya does research in the fields of molecular biology, cell biology, and cancer biology.
Abhay R. Vasavada is a well-known ophthalmologist who founded Raghudeep Eye Clinic (REH) and Iladevi Cataract and IOL Research Centre (ICIRC) in Ahmedabad, India. In 2011, the American Society of Cataract and Refractive Surgeons (ASCRS) gave him the Binkhorst Medal Lecture, making him the first Indian and just the second Asian to get the honour. He has almost 140 publications to his credit.
Kaid Johar SR is an Associate Professor in Department of Zoology and Biomedical TechnologyGujarat University, who specialized in cell and molecular biology, ophthalmology, cancer, and toxicology. He has almost 50 publications in prestigious journals.
The Exosome Manufacturing Gap
Dr Deepika Arora is an accomplished professional with expertise in project management, process improvement, and operational excellence. She brings strong scientific expertise and experience in prolific biologics, contributing to innovation and quality-driven outcomes. With a commitment to continuous learning, she has led cross-functional initiatives across diverse industries and writes on leadership, strategy, and professional development.
Aditya Banerjee is a senior scientist specialising in stem cell biology, regenerative medicine, and translational research. His work focuses on GMP-compliant cell therapy manufacturing, exosome research, and quality systems. Passionate about advancing scientific innovation, he writes on emerging biotechnologies, laboratory excellence, and their translation into meaningful clinical applications.
Perspectives on the Vaccine Industry
As a Senior Consultant in Bioprocessing Strategy at Merck with over 14 years of
international biopharma experience, Josephine Cheng focuses on vaccine and mRNA market segments, where she translates strategies into market initiatives to enable the utilisation of best-in-class technologies and transforms industry insights into sustainable business strategies.
Josephine obtained Bachelor's and Master's degrees in Bio-resource's; Agriculture from the National Taiwan University.
press releasesRead more...
Merck Opens €300 Million Asia-Pacific Bioprocessing Center in Daejeon, South Korea
Merck a leading science and technology company today opened its new AsiaPacific Bioprocessing Production Center in Daejeon South Korea The center represents an investment of more than million the companys largest Life Science investment in AsiaPacific to date
Flagship Pioneering Forms Etcelera to Move Drug Discovery from Probability to Prediction
Flagship Pioneering a scientific innovation engine for transformative platforms and products today announced the formation of Etcelera a company created by the merger of the platforms of Cellarity Cellarity Platform Inc Etiome and Empress Therapeutics to pioneer causal intelligence in human biology...
Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application of Toripalimab (Subsutaneous Injection) for the 1st-Line Treatment of HER2-Expressing Urothelial Carcinoma
Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies announced that the supplemental new drug application for the companys product toripalimab injection subcutaneous injection
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Primary Immune Thrombocytopenia
HUTCHMED China Limited today announces that the US Food and Drug Administration FDA has granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia ITP an autoimmune disorder that can lead to increased
Transpharmation Ltd. Announces Strategic Acquisition of OrganoTherapeutics SARL
Were delighted to announce the strategic acquisition of OrganoTherapeutics SARL a leader in patientderived organoid technologies that advance the discovery and development of novel therapies for neurodegenerativeCNS disorders
EVERSANA Expands Global Commercialization and AI-Powered HEOR Capabilities with Acquisition of U.K.-based Estima Scientific
EVERSANA a global provider of modern AIpowered commercial services for the biopharmaceutical industry today announced the acquisition of Estima Scientific an innovative Londonbased health economics and outcomes research HEOR technology and services company
EventsRead more...
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
LATEST NEWSRead more...
Edison Scientific Enters into Agreement with Pfizer to Advance Drug Research and Development
Edison Scientific has entered into an agreement with Pfizer to introduce its Edison AI Platform and AI scientist Kosmos across Pfizers biopharmaceutical research and development activities The collaboration will combine Edison Scientifics artificial intelligence AI technology with Pfizers scientific...
Appian and PSI CRO Partner to Advance AI-driven Clinical Trial Operations
Appian and PSI CRO have entered into a strategic partnership to introduce an artificial intelligence AIpowered solution for clinical trial site identification and selection The solution is now live and is designed to automate site selection across different therapeutic areas medical conditions and...
Adalvo Acquires Romiplostim Biosimilar from Enzene
Adalvo has acquired a romiplostim biosimilar programme from Enzene expanding its portfolio of biosimilars and strengthening its presence in complex biological medicines The programme references Nplate romiplostim a medicine used to treat immune thrombocytopenia ITP in adults and children with chroni...
Twist Bioscience Launches Express Screening Antibodies for Faster Characterisation
Twist Bioscience has expanded its antibody production and characterisation portfolio with the launch of Twist Express Screening Antibodies a service designed to help researchers evaluate large numbers of antibody candidates more quickly The service uses a highthroughput cellfree production process t...
Astellas Enters into Agreement with Audax for Immuno-Oncology Candidate DAX-044
Astellas Pharma and Audax Biosciences have entered into an exclusive option and licence agreement for DAX an investigational antibodycytokine fusion being developed for cancer immunotherapy DAX is designed to deliver interleukin IL an immuneactivating protein more selectively to the tumour microenvi...
Sumitomo Pharma’s Enzomenib Receives Breakthrough Therapy Designation for Relapsed or Refractory KMT2A-Rearranged Acute Leukaemia
Sumitomo Pharma America has announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to enzomenib DSP for treating patients with relapsed or refractory acute leukaemia carrying a KMTA gene rearrangement
